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Abstract
Background: Molecules Interacting with CasL (MICAL1), a multidomain flavoprotein monoxygenase, is strongly
involved in the mechanisms that promote cancer cell proliferation and survival. Activation of MICAL1 causes an up-
regulation of reactive oxygen species (ROS) in HeLa cells. ROS can function as a signaling molecule that modulates
protein phosphorylation, leading to malignant phenotypes of cancer cells such as invasion and metastasis. Herein, we
tested whether MICAL1 could control cell migration and invasion through regulating ROS in breast cancer cell lines.
Methods: The effects of depletion/overexperssion of MICAL1 on cell invasion rate were measured by matrigel-based
transwell assays. The contents of ROS in breast cancer cells were evaluated by CM2-DCFHDA staining and enhanced
lucigenin chemiluminescence method. RAB35 activity was assessed by pulldown assay. The relationship of RAB35 and
MICAL1 was evaluated by immunofluorescence, coimmunoprecipitation, immunoblotting and co-transfection
techniques. Immunoblotting assays were also used to analyze Akt phosphorylation level.
Results: In this study, we found that depletion of MICAL1 reduced cell migration and invasion as well as ROS
generation. Phosphorylation of Akt was also attenuated by MICAL1 depletion. Likewise, the over-expression of MICAL1
augmented the generation of ROS, increased Akt phosphorylation, and favored invasive phenotype of breast cancer
cells. Moreover, we investigated the effect of EGF signaling on MICAL1 function. We demonstrated that EGF increased
RAB35 activation and activated form of RAB35 could bind to MICAL1. Silencing of RAB35 repressed ROS generation,
prevented Akt phosphorylation and inhibited cell invasion in response to EGF.
Conclusions: Taken together, our results provide evidence that MICAL1 plays an essential role in the activation of ROS/
Akt signaling and cell invasive phenotype and identify a novel link between RAB35 and MICAL1 in regulating breast
cancer cell invasion. These findings may provide a basis for designing future therapeutic strategy for blocking breast
cancer metastasis.
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Background
MICAL1 is a member of molecules Interacting with
CasL (MICAL) family discovered in 2002 [1]. In spite of
its wide distribution in the nervous system [2], MICAL1
has been found expressed in various human normal cells
as well as cancer cell lines, including melanoma and
HeLa cells [3, 4]. Combined with the characteristic of
anti-apoptosis, MICAL1 has been proven to be involved
in cancer cell growth and survival regulation [3, 4].
MICAL1 has four conserved domains: an N-terminal fla-
vin adenine dinucleotide (FAD) binding domain, a calpo-
nin homology (CH) domain, a Lin11, Isl-1 and Mec-3
(LIM) domain and a C-terminal coiled-coil (CC) do-
main, where the FAD domain is responsible for the
major portion of the MICAL1’s function [5]. Studies
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have showed that FAD domain of MICAL1 contains fla-
vin mono-oxygenase activity and has the ability to pro-
duce ROS [3, 6]. It has been well documented that
increased oxidative stress and ROS production is crucial
for breast cancer development and maintenance of its
malignant state [7, 8]. Results from our studies have also
shown that when breast cancer cells receive signals from
their microenvironment, such as EGF, LPA and hypoxia,
ROS level in cells may increase and functions as second
messengers in intracellular signaling cascades which in-
duce their migratory and invasive properties [9–11].
However, whether MICAL1 could influence cell meta-
static property by regulating ROS level in breast cancer
cells remains to be determined.
It is now known that MICAL1 displays an auto-
inhibitory mechanism to control its biomolecular func-
tion. Normally, the MICAL1 CC domain binds to its
LIM domain to mediate the auto-inhibition. Removal of
the CC domain from MICAL1 or affect the binding of
CC domain to its LIM domain may cause the activation
of its mono-oxygenase domain, leading to ROS produc-
tion and F-actin assembly alteration. Actually, MICAL1
is a highly regulated protein, the auto-inhibition state
could be relieved by the interaction occur within CC do-
main and other proteins such as RAB1 and Plexin under
various cellular conditions [12, 13]. RABs are the largest
family of small GTPases and involved in the control of
intracellular membrane trafficking and cell motility
through interaction with specific effector molecules [14,
15]. By a yeast two-hybrid assay, previous study has sys-
tematically screened the ability of MICAL1 binding for
all the members of Rab family and found that GTP-
bound RAB35 was one of the few members which inter-
acted strongly with MICAL1 [16].
Like all GTPases, RAB35 activity is under tight con-
trol, which is mediated by guanine nucleotide exchange
factors (GEFs) and GTPase activating proteins (GAPs)
that catalyze GTP exchange and hydrolysis, respectively
[14]. Notably, RAB35 has ample opportunities to influ-
ence diverse cell signaling, resulting in functional prom-
iscuity on tumor initiation and progression, and the
activity of RAB35 in tumor is of tremendous research
interest. It has been shown that RAB35 functions as a
tumor suppressor and attenuated signaling downstream
of Arf6 [17]. However, Studies on Drosophila cultured
cells have led to the suggestion that RAB35 may pro-
mote the assembly of actin filaments during bristle de-
velopment and increase filopodia formation [18].
Similarly, there are also report that RAB35 is over-
expressed in ovarian cancer [19]. Recent studies includ-
ing the results from our laboratory also showed that
RAB35 activation could be act as a positive regulator of
cell shape, phagocytosis as well as migration in various
types of cells [20–22]. Several studies have highlighted a
link between RAB35 and MICAL-l1, a similar protein to
MICAL1, which revealed that RAB35 could use MICAL-
l1 as its membrane hub effector [23, 24]. Although
RAB35 could recruit different effectors to perform spe-
cific biological process, it remains unclear whether and
if so, the biological relevance of RAB35 binding to
MICAL1 in breast cancer cells. In this study, we exam-
ined whether knockdown or overexpression of MICAL1
could influence ROS generation and cell migration firstly,
and then explored the mechanism underlying MICAL1
action by examining the effect of RAB35 blockage/acti-
vation on those process.
Methods
Cell and plasmids
Human breast cancer cell lines MDA-MB-231, MCF-7,
T47D, BT474 and MDA-MB-468 were obtained from
the Cell Biology Institute of Chinese Academy of
Sciences (Shanghai, China). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, high
glucose) (Hyclone, Thermo Scientific, Waltham, MA,
USA) supplemented with 10 % (v/v) fetal bovine serum
(FBS) (Hyclone) and antibiotics (100 U/mL streptomycin
and 100 μg/mL penicillin) (Invitrogen, Carlsbad, USA)
in a humidified incubator at 37 °C with 5 % CO2. Cells
were grown on coverslips for fluorescence staining and
on plastic dishes for protein extraction. Cells were made
quiescent by serum starvation overnight followed by
EGF (R&D Systems, Minneapolis, MN, USA) treatment.
The RAB35-Q67L (constitutively active, CA), RAB35-
S22N (dominant negative, DN) and wild-type RAB35
(WT) plasmids were kindly provided by Dr. Matthew P.
Scott (Department of Developmental Biology, Stanford
University, USA). The PCR products were cloned into
the pEGFP-N1 vector (Clontech, Palo Alto, CA, USA).
Human MICAL1 cDNA clone was purchased from You-
bio (Hunan, China). The full-length MICAL1 DNA was
amplified from pOTB7-MICAL1 plasmid using the fol-
lowing primer set, sense: 5′-CCCAAGCTTGCCACCA
TGGCTTCACCTACCTCCA-3′, antisence: 5′-CCAA
CTCGAGGCCCTGGGCCCCTGTCCCCAAGGCCA-3′.
In these primers, Hind III and Xho I restriction site
sequences have been underlined. The polymerase chain
reaction (PCR) products were cloned into the pCMV-C-HA
vector (Beyotime, Nantong, China). Truncated MICAL1
lacking CC domain (residues 1–799) and truncated
MICAL1 containing CC domain (residues 800-1068)
were also created as previously described [3]. The cells
were seeded in 6-well plates, cultured to 80 ~ 90 % con-
fluence, and then transiently transfected with those
plasmids by using FuGENE HD Transfection Reagent
(Promega Corporation, Madison, WI, USA) according
to the manufacturer’s instructions.
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siRNA knockdown studies
The sequences of small interfering RNA (siRNA) for
MICAL1 were as follows: #1, 5′-GUCUCUGCCUUUGA-
CUUCATT-3′, #2, 5′-CUGCAGAACAUUGUGUA-
CUTT-3′, and #3, 5′-CUCGGUGCUAAGAAGUUCU
TT-3′; siRNA for RAB35 was: 5′-GCAGCAACAACA-
GAACGAUTT-3′ and the sequence of control siRNA was
5′-UUCUCCGAACGUGUCACGUTT-3′ (GenePharma,
Shanghai, China). Cells were transfected with siRNA by
Lipofectamine 2000 according to the manufacturer’s
instruction.
Migration and invasion assays
For wound healing assay, breast cancer cells were seeded
in a 96-well plate. Approximately 24 h later, when cells
were 95 ~ 100 % confluent, cells were incubated over-
night in DMEM and wounding was performed by scrap-
ing through the cell monolayer with a 10 μl pipette tip.
Medium and nonadherent cells were removed, and cells
were washed twice with PBS, and new medium with or
without EGF was added. Cells were permitted to migrate
into the area of clearing for 18 h. Wound closure was
monitored by visual examination under microscope
(Carl Zeiss Meditec).
For transwell migration assay, breast cancer cells in
exponential growth were harvested, washed, and sus-
pended in DMEM without FBS. Cells (2 × 105/200 μl)
were seeded into polycarbonate membrane inserts (8 μm
pore size) in 24-transwell cell culture dishes. Cells were
allowed to attach to the membrane for 30 min. The
lower chamber was filled with 600 μl DMEM with
EGF or with 10 % FBS. Cells were permitted to mi-
grate for 12 h. After the incubation, stationary cells
were removed from the upper surface of the mem-
branes. The cells that had migrated to the lower sur-
face were fixed and stained with 0.1 % crystal violet.
Cell invasion was analyzed using the same protocol as
for cell transwell migration, but with the use of
matrigel (BD Bioscience) pre-coated cell culture in-
serts. Cells were permitted to invade for 24 h.
Coimmunoprecipitation and immunoblotting assays
Coimmunoprecipitation assays were performed as
previously described. Briefly, cell lysates were incubated
with antibody at 4 °C overnight. Antibody-bound com-
plexes were precipitated with protein A +G agarose beads
(Beyotime) and eluted by rinsing buffer, then the agarose-
associated protein complexes were dissolved in SDS
loading buffer and analyzed by immunoblotting assays.
Sample protein extraction and concentration deter-
mination of whole cells were performed as previously
described [9]. Briefly, equal amounts of protein were run
on SDS polyacrylamide gels and transferred to nitrocel-
lulose membrane. The resulting blots were blocked with
5 % non-fat dry milk and probed with antibodies. The
following antibodies were used: GAPDH (KangChen),
MICAL1 (proteintech) (Santa Cruz Biotechnology), RAB35
(BD Biosciences) (ABclonal Technology), Akt, P-Akt, HA
and GFP antibodies (Cell Signaling). Protein bands were
detected by incubating with HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology) and visualized with
ECL reagent (Millipore).
Pulldown assays
RAB35 activity was measured by pulldown assays as de-
scribed previously [22]. In brief, the GST fusion RBD35
was purified from BL21 bacteria and incubated with cell
lysates. Then the complexs were incubated with Mag-
neGST Glutathione Particles (Promega) for 30 min on a
rotating wheel at 4 °C. After washed with washing buffer
and collected by magnet in a magnetic stand (Promega),
the beads were solubilized in 2 × SDS loading buffer, and
then subjected to immunoblotting assays with antibody
against RAB35.
Immunofluorescence and immunohistochemistry assays
Cells used for immunostaining were fixed in ice-cold
methanol for 20 min, permeabilized in 0.1 % Triton X-
100 and blocked in PBS containing 1 % BSA for 1 h at
room temperature. The cells were incubated with pri-
mary antibody overnight at 4 °C followed by incubation
with FITC or rhodamine conjugated secondary antibody
for 1 h at room temperature within a moist chamber.
After wash with PBS, the samples were mounted with
DAPI Fluoromount G (Southern Biotech). Images were
acquired using an Olympus BX51 microscope coupled
with an Olympus DP70 digital camera.
Measurement of ROS
For intracellular H2O2 staining, 1 × 10
5 cells were seeded
on a coverslip placed in a 6-well plate and incubated
overnight. After treated with appropriate inhibitors and
stimuli as detailed elsewhere in the text, the cells were
stained with 5 μM 2′,7′-dichlorofluorescein diacetate
(CM2-DCFHDA) (Invitrogen) for 15 min at 37 °C. After
wash with PBS, the cover slips were mounted on glass
slides. Images were collected using an Olympus BX51
microscope coupled with an Olympus DP70 digital
camera.
The level of superoxide anions in the cells was mea-
sured using the enhanced lucigenin chemiluminescence
method. The homogenate supernatant of total cellular
protein was diluted in modified HEPES buffer. The reac-
tion started by addition of 5 μM dark-adapted lucigenin
(Sigma). Light emission was measured for 10 times in
10 min with a luminometer (20/20n, Turner), and aver-
age values were calculated and expressed as mean light
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unit (MLU) per min per milligram of protein, which rep-
resented the level of superoxide anions.
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical software program (Version 19.0; SPSS, Chicago, IL,
USA). Error bars represent standard error of mean
S.E.M, the significance of difference in two groups was
analyzed by Student’s t test. P < 0.05 represents statistical
significance and P < 0.01 represents sufficiently statistical
significance (two tailed).
Results
MICAL1 regulates breast cancer cell migration and
invasion
To examine the function of MICAL1 in breast cancer
progression, we silenced MICAL1 expression in human
breast cancer MDA-MB-231 cells with siRNA for
MICAL1. The cells were lysed and the knockdown effi-
ciency was determined by immunoblotting assays
(Fig. 1a). Enhanced motility of breast cancer cells is a
critical step in promoting tumor metastasis, but roles of
MICAL1 in breast cancer motility remain to be deter-
mined. We first explored the effects of MICAL1 silen-
cing on breast cancer cell migration in vitro. By wound
healing assay and transwell migration assay, we found
that siMICAL1-transfected MDA-MB-231 cells exhib-
ited decreased migratory potential than the control cells
(Fig. 1b&c). To confirm the role of MICAL1 in regu-
lating breast cancer cell motility, we also performed
the same transfection (siMICAL1 #3) in MDA-MB-
231 and MCF-7 cells, and found that silencing
MICAL1 also inhibited cell invasion in those cells
(Fig. 1d&g). In contrast, increased invasive potential
was observed in both cells overexpressed MICAL1
(Fig. 1e&f ). These results indicate that MICAL1 plays
a positive role in regulating breast cancer cell migra-
tory and invasive potential.
MICAL1 forms complexes with active form of RAB35
A number of coregulators, such as RAB1, is reported dy-
namically bind to MICAL1 and modulate its activity.
We hypothesized that during migration, MICAL1 activ-
ity might be induced through a similar mechanism. By a
yeast two-hybrid assay, GTP-bound RAB35 was identi-
fied could interacted strongly with MICAL1 [16]. In this
study, immunoflurescence analysis showed that MICAL1
was partially colocalized with RAB35 in both MDA-MB-
231 and MCF-7 cells (Fig. 2a). Furthermore, coimmuno-
precipitation experiments were performed to determine
whether RAB35 binds to MICAL1 in cells. GFP-RAB35
and/or HA-MICAL1 vector was cotransfected in
HEK293T cells, and the protein complexes were immu-
noprecipitated by anti-GFP antibody. We noticed that a
significant amount of MICAL1 was pulled down in the
GFP-RAB35-expressing cells but not in the control cells,
indicating that MICAL1 binds to RAB35 in HEK293T
cells (Fig. 2b). The interaction between MICAL1 and
RAB35 was also confirmed in MCF-7 cells, which
showed that interaction between endogenous MICAL1
and RAB35 (WT) as well as active form of RAB35 (CA),
but not inactive form of RAB35 (DN) (Fig. 2c). We also
showed interaction between endogenous RAB35 and
MICAL1 in coimmunoprecipitation assays in both
MDA-MB-231 and MCF-7 cells (Fig. 2d).
Activation of RAB35 is necessary for EGF-induced invasion
We screened the protein levels of MICAL1 and RAB35
in five breast cancer cell lines and found that those two
proteins were abundantly expressed (Fig. 3a). RAB35 is
well characterized in the Wnt5a pathway, which was
identified as a potent modulator of MCF-7 breast cancer
cell migration [22]. Firstly, we examined whether RAB35
could also be activated by EGF in MCF-7 cells. Immuno-
blotting assays showed weak but detectable steady state
expression of activated RAB35, which was clearly aug-
mentated after 5-15 min of EGF treatment (Fig. 3b).
Next, to verify that RAB35 could impact cell motility, we
transfected cells with siRNA against RAB35 (Fig. 3c),
and examined its effect on MCF-7 cell invasion. As
shown in Fig. 3d, following EGF or FBS stimulation,
numbers of invasive cells were decreased significantly in
the group transfected with siRAB35, compared to the
cells transfected with sictrl. Invasion assays results also
showed that knockdown of MICAL1 delayed the inva-
sive ability of RAB35 (CA)-expressing MDA-MB-231
cells (Fig. 3e). Taken together, these experiments demon-
strated that RAB35 was required for EGF-induced inva-
sion in breast cancer cells.
RAB35 and MICAL1 mediate EGF-induced ROS generation
MICAL1 is well characterized in the ROS generation,
which has been associated with cancer cell invasion. To
verify RAB35 and MICAL1 could impact EGF-mediated
ROS, we transfected cells with siRAB35 or siMICAL1,
and then examined its effect on ROS generation. As
shown in Fig. 4a, weak but detectable steady state pro-
duction of ROS was showed in control cells. After
30 min of EGF treatment, ROS level was clearly in-
creased in the control cells transfected with the empty
vector, but it was down-regulated in the cells transfected
with siRAB35 or siMICAL1. Meanwhile, ROS generation
in serum-cultured MCF-7 cells is also inhibited by either
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Fig. 1 MICAL1 regulates breast cancer migration and invasion in vitro. a MDA-MB-231 cells were transfected with negative control siRNA or siRNA
specifically targeting MICAL1 (siMICAL1). 48 h later, total protein extracts from cells were analyzed by immunoblotting analysis for MICAL1 expression.
*: P < 0.05 in the cells transfected with or without siRNA targeting MICAL1. (b&c) Representative transwell migration (b) and wound healing assay (c)
images of control and MICAL1 silencing MDA-MB-231 cells. Quantification of migration rates was analyzed respectively. d MDA-MB-231
cells transfected with control siRNA or siMICAL1, and the quantification of cell invasion rate was performed. (e&f) MDA-MB-231 (e) and
MCF-7 cells (f) were transfected with MICAL1 or empty vector, and the quantification of cell invasion rate was performed. *:P < 0.05, **:P < 0.01 in the
cells transfected with HA–MICAL1 relative to cells transfected with the corresponding vector. g MCF-7 cells transfected with control siRNA or siMICAL1,
and the quantification of cell invasion rate was performed. *: P < 0.05 in the siMICAL1 cells relative to siRNA control cells
Deng et al. BMC Cancer  (2016) 16:489 Page 5 of 11
siRAB35 or siMICAL1 transfection (Fig. 4b). It is worth
noting that cells expressing full-length MICAL1 or FAD-
LIM domain of MICAL1 induced high levels of ROS in
transfected cells. However, upon transfection of the CC
domain, the levels of ROS were only slightly higher
than the baseline levels (Fig. 4c). Taken together,
these experiments demonstrated that both RAB35 and
MICAL1 were required for ROS generation in breast
cancer cells.
ROS mediates RAB35/MICAL1 signals and regulates cell
invasion via phosphorylated Akt
PI3K/Akt plays a key role in migratory potential regula-
tion. To probe the involvement of PI3K/Akt activation
in RAB35/MICAL1-induced cell motility, we transfected
MCF-7 cells with siRAB35 or siMICAL1 and P-Akt ex-
pression was detected by immunoblotting assays. Our
observations have yielded evidence that the level of P-
Akt was markedly blocked after the silencing of
MICAL1. Consistently, P-Akt was higher when MICAL1
or RAB35-Q67L overexpressed in MCF-7 cells
(Fig. 5a&b). Together, these results indicated that
RAB35 and MICAL1 could affect the level of P-Akt.
Moreover, pre-treatment with ROS inhibitor NAC inhib-
ited P-Akt level (Fig. 5c) as well as cell invasion (Fig. 5d).
NAC and LY294002 pretreatment also delayed the in-
creased invasion activity induced by overexpression of
MICAL1 (Fig. 5e). Collectively, these data indicate that
the activation of RAB35/MICAL1 may facilitate ROS
generation, which leading to PI3K/Akt signaling activa-
tion and breast cancer cell invasion.
Discussion
While there is only one gene encoding MICAL in Dros-
ophila, vertebrates contain three genes encoding MICAL
isoforms indicated as MICAL1, MICAL2 and MICAL3.
Furthermore, MICAL-like forms, which were absent of
FAD domain, also have been identified exist in verte-
brates. In Drosophila, MICAL selectively oxidizes Met
44 residue within the D-loop of actin, thereby destabiliz-
ing F-actin and inhibiting local assembly [25]. MICAL1
has the most closely related domain architecture to
Drosophila MICAL [3], however, to date, only a few re-
ports have been published to describe the functions of
MICAL1 during cancer progression. Previous studies
have shown that aberrant activation MICAL1 is a nega-
tive regulator of apoptosis and contributes to malignant
progression of melanoma [4]. In the present study, we
demonstrate that knockdown of MICAL1 has favorable
effect on preventing cell migration and invasion. We
also show that ROS acts as downstream of MICAL1 to
regulate cell invasion. Moreover, we determine a novel
link between RAB35 and MICAL1 in regulating EGF-
induced breast cancer cell invasion. Taken together, we
demonstrate for the first time that MICAL1 may play a
potential role in breast cancer cell motility and shed
Fig. 2 Active form of RAB35 binds to MICAL1. a Representative micrographs of MDA-MB-231 and MCF-7 cells stained for RAB35 (green) and
MICAL1 expression (red) by immunofluorescence assay. Scale bar, 10 μm. b Coimmunoprecipitation experiments were performed with HEK293T
cells cotransfected with HA-tagged MICAL1 and GFP-tagged RAB35. c MCF-7 cells were transfected with GFP-tagged RAB35 (WT), RAB35 (DN) or RAB35
(CA), and then immunoprecipitated with anti-GFP antibody, followed by immunoblotting analysis for RAB35 and MICAL1. d Binding of endogenous RAB35
to MICAL1 was detected in MDA-MB-231 cells and MCF-7 cells by coimmunoprecipitation experiments. n= 3 for all experiments
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light on new therapeutic target against breast cancer in-
vasion and metastasis.
Enhanced motility of cancer cells is a critical abil-
ity in promoting tumor metastasis and mortality of
patients. Here, we delineated the role of MICAL1 in
regulating breast cancer cell motility. Our results
showed that the migratory and invasive ability of
breast cancer cells induced by EGF or FBS stimula-
tion decreased significantly after MICAL1 silencing
in vitro. Consistently, MICAL1 overexpression in the
cancer cells accelerated their motility behavior. Re-
cent study showed that MICAL2-positive cells pecu-
liarly localized at the primary human gastric cancer
invasive front and MICAL2 knock-down in cancer
cells resulted in mesenchymal to epithelial transition
[26]. Similar with those results, in the present study, we
uncovered an essential role of MICAL1 in promoting mi-
gration and invasion of breast cancer cells. Given our
Fig. 3 Effect of RAB35 on breast cancer cell invasion. a RAB35 and MICAL1 expressions were examined by immunoblotting in several types of
malignant breast cancer cell line. b MDA-MB-231 cells were incubated with EGF (10 ng/mL) for indicated times, and analyzed for RAB35 activity
by pulldown assays. *P < 0.05 in the cultures with EGF relative to the cultures without EGF. c MCF-7 cells were transfected with negative control
siRNA or siRAB35. 48 h later, total protein extracts from cells were analyzed by immunoblotting analysis for RAB35 expression. Western blot bands
corresponding to RAB35 were quantified and normalized against GAPDH level. **: P < 0.01 in the siRAB35 cells relative to control siRNA cells. d
MCF-7 cells transfected with control siRNA or siRAB35, and the quantification of cell invasion rate was performed. *: P < 0.05 in the siMICAL1 cells
relative to control siRNA cells. e Invasion assays results showed that knockdown of MICAL1 delayed cell invasion in RAB35 (CA)-expressing
MDA-MB-231 cells. *:P < 0.05. **:P < 0.01
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observation that silencing MICAL1 specifically inhibited
EGF induced cell invasion, it will be interesting to eluci-
date the exact mechanisms by which EGF regulate
MICAL1’s function.
ROS are highly reactive molecules generated by in-
complete reduction of oxygen, including superoxide,
hydrogen peroxide, and hydroxyl radical et al. Of
note, increased oxidative stress and ROS production
was present in many human metastatic tumors, and
the roles of ROS in triggering signaling pathways for
cell migration and invasion have been well estab-
lished [27, 28]. Here, we demonstrated that the in-
creased level of ROS production after EGF
stimulation was markedly blocked by silencing of
MICAL1. Moreover, cells only expressing CC domain
from MICAL1 displayed lower levels of ROS when
compared with cells overexpressed full-length of
MICAL1. Our finding is consistent with a previous
report that HeLa cells transfected with the FAD do-
main from MICAL1 augmented ROS levels [3]. Con-
sistently, the levels of ROS were significantly
attenuated upon transfection of the enzymatically
impaired FAD domain mutant [3]. Therefore, it is
proposed that during EGF stimulation, MICAL1, es-
pecially for its FAD domain, facilitates the production
of ROS, helping to promote the migratory and inva-
sive ability of breast cancer cells.
As due to their very nature, ROS cannot impart cell
migratory functions directly. Activation of PI3K/Akt
by ROS was shown be an important mechanism to
mediate breast cancer cell migration by LPA [9]. In
keeping with this idea, MICAL1-induced breast can-
cer cell invasion might be PI3K/Akt dependent. Our
observations have yielded evidence that the increase
of P-Akt was markedly blocked after the silencing of
MICAL1. Consistently, P-Akt was higher in MICAL1
overexpressed breast cancer cells. It is worth noting
that the effect of ROS on lung cancer cell migratory
functions is dependent on Akt activity [29]. Here, we
also found that P-Akt level as well as cell invasion
was blocked by application of ROS scavenger NAC.
Therefore, Akt is more likely the target of ROS
downstream of MICAL1 to regulate breast cancer cell
motility.
RAB35 may functions downstream of growth factor
receptors and associates with PI3K. Further, the
Fig. 4 RAB35/MICAL1 regulates ROS generation. a Effects of RAB35 and MICAL1 on H2O2 generation. MCF-7 cells transfected with siRAB35 or
siMICAL1 were in serum-free media overnight. Representative micrographs of those cells incubated with EGF (10 ng/mL for 30 min) and stained
with CM2-DCFHDA. *: P < 0.05 in the cultures with EGF relative to the cultures without EGF.
#:P < 0.05 in the cultures with EGF plus siRAB35 or
siMICAL1 relative to the cultures with EGF. Scale bar, 100 μm. b Effects of RAB35 and MICAL1 on O2− generation in MCF-7 cells. *: P< 0.05 in the cultures
transfected with siRAB35 or siMICAL1 relative to the cultures with control siRNA. c Quantification of O2
− levels in the cells transfected with HA–MICAL1, HA
tagged MICAL1 FAD-LIM domain and CC domain. *: P< 0.05 in the cells transfected with HA–MICAL1 or HA–FAD-LIM relative to cells transfected with
vector. #: P< 0.05 in the cells transfected with CC domain relative to cells transfected with HA–MICAL1 or HA–FAD-LIM domain
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expression of GTP-bound RAB35 is necessary and suffi-
cient for PI3K/Akt signaling activation and apoptosis re-
sistance in human tumors [30]. Our previous work
suggested a link between RAB35 activity and in-
creased breast cancer cell migration [22]. Although
some studies showed that RAB35 has the opposite ef-
fect on the migration in some kind of cancer cells
[17, 31], in the present work, we found that EGF in-
duced RAB35 activation, while blocking RAB35 ex-
pression greatly abolished EGF-induced cell invasion.
These results suggest that EGF might promote cell
invasion in breast cancer cells by activating RAB35.
Until now, limited knowledge was concerning the
regulation of MICAL1 function by EGF signaling in
breast cancer cells. In the current study, we deter-
mined that RAB35 and MICAL1 coimmunoprecipi-
tated, and this interaction was disrupted when RAB35
was inactivated. We also observed that MICAL1 si-
lencing delayed the increased invasive ability of
RAB35 (CA)-expressing breast cancer cells. Moreover,
knockdown RAB35 reduced ROS level as well as
P-Akt level in breast cancer cells. Besides the fact
that CC domain of MICAL-l1 interacts with active
mutants of RAB35 [23], and the inhibitory effect of
MICAL on ROS generation is thought to be
dependent on the binding of CC domain to its LIM
domain, therefore, we speculated that active form of
RAB35 might be able to release MICAL1 auto-
inhibition by directly binding to the CC domain of
MICAL1, thereby allowing ROS generation and pro-
moting cell migratory and invasive properties.
Conclusions
Our results provide evidence that MICAL1 plays an es-
sential role in the activation of ROS/Akt signaling and
cell invasive phenotype and identify a novel link between
RAB35 and MICAL1 in regulating breast cancer cell in-
vasion. Although the current study has contributed to
the mechanistic understanding the role of MICAL1 in
breast cancer cell migration and invasion, the issue as to
how RAB35 precisely regulates MICAL1 in breast
cancer cells is unlikely to be settled in this paper. In
Fig. 5 Effects of RAB35 and MICAL1 on ROS-modulated Akt activity. a MCF-7 cells transfected with siRAB35 or siMICAL1, and protein
levels of P-Akt and Akt were examined. Western blot bands corresponding to P-Akt were quantified and normalized against Akt levels. *: P < 0.05 in
the cultures transfected with siRAB35 or siMICAL1 relative to the cultures with control siRNA. b MCF-7 cells were transfected with MICAL1 or RAB35
(CA) plasmids, and the total cellular proteins were extracted and analyzed for expressions of P-Akt and Akt by immunoblotting assays. *:P < 0.05 in the
cells transfected with HA–MICAL1 or GFP–RAB35 (CA) relative to cells transfected with the corresponding vector. c MCF-7 cells were treated with
2 mM NAC for 1 h, and then the total protein extracts from cells were analyzed by immunoblotting assays for P-Akt and Akt expression. d Effect of
NAC on cell invasion. After cultured in serum-free medium overnight, MCF-7 cells were pretreated with 2 mM NAC for 1 h, and then were stimulated
with EGF (10 ng/mL) or 10 % FBS for 24 h. Quantifications of cells on the lower surface of the membrane were performed and shown. *: P < 0.05,
**: P < 0.01 in the cultures with NAC relative to the cultures without NAC. e Invasion assays results showed that LY294002 and NAC delayed cell
invasion in MICAL1-expressing MCF-7 cells. *:P < 0.05. **:P < 0.01
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conclusion, results obtained in this study clearly estab-
lish a new mechanistic connection between RAB35 and
MICAL1 in the context of ROS generation, which could
be essential in promoting cell migration and invasion
during breast cancer cell metastasis.
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